The antifolate activity of tea catechins

被引:117
作者
Navarro-Perán, E
Cabezas-Herrera, J
García-Cánovas, F
Durrant, MC
Thorneley, RNF
Rodríguez-López, JN
机构
[1] Univ Murcia, Fac Biol, Dept Bioquim & Biol Mol A, Grp Invest Enzimol, E-30100 Murcia, Spain
[2] Univ Murcia, Hosp Virgen Arrixaca, Serv Anal Clin, E-30001 Murcia, Spain
[3] John Innes Ctr Plant Sci Res, Computat Biol Grp, Norwich NR4 7UH, Norfolk, England
[4] John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England
关键词
D O I
10.1158/0008-5472.CAN-04-3469
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A naturally occurring gallated polyphenol isolated from green tea leaves, (-)-epigallocatechin gallate (EGCG), has been shown to be an inhibitor of dihydrofolate reductase (DHFR) activity in vitro at concentrations found in the serum and tissues of green tea drinkers (0.1-1.0 mu mol/L). These data provide the first evidence that the prophylactic effect of green tea drinking on certain forms of cancer, suggested by epidemiologic studies, is due to the inhibition of DHFR by EGCG and could also explain why tea extracts have been traditionally used in "alternative medicine" as anticarcinogenic/antibiotic agents or in the treatment of conditions such as psoriasis. EGCG exhibited kinetics characteristic of a slow, tight-binding inhibitor of 7,8-dihydrofolate reduction with bovine liver DHFR (K-1 = 0.109 mu mol/L), but of a classic, reversible, competitive inhibitor with chicken liver DHFR (K-1 = 10.3 mu mol/L). Structural modeling showed that EGCG can bind to human DHFR at the same site and in a similar orientation to that observed for some structurally characterized DHFR inhibitor complexes. The responses of lymphoma cells to EGCG and known antifolates were similar, that is, a dose-dependent inhibition of cell growth (IC50 = 20 mu mol/L for EGCG), G(0)-G(1) phase arrest of the cell cycle, and induction of apoptosis. Folate depletion increased the sensitivity of these cell lines to antifolates and EGCG. These effects were attenuated by growing the cells in a medium containing hypoxanthine-thymidine, consistent with DHFR being the site of action for EGCG.
引用
收藏
页码:2059 / 2064
页数:6
相关论文
共 21 条
[1]  
Backus HHJ, 2000, INT J CANCER, V87, P771, DOI 10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO
[2]  
2-V
[3]   DIHYDROFOLATE-REDUCTASE FROM BOVINE LIVER - ENZYMATIC AND STRUCTURAL-PROPERTIES [J].
BAUMANN, H ;
WILSON, KJ .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1975, 60 (01) :9-15
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[6]   Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase:: correlations between enzyme selectivity and stereochemistry [J].
Cody, V ;
Luft, JR ;
Pangborn, W ;
Gangjee, A ;
Queener, SF .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2004, 60 :646-655
[7]  
CODY V, 1992, ANTI-CANCER DRUG DES, V7, P483
[8]  
CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P34
[9]  
Correa, 2000, Ann Epidemiol, V10, P476, DOI 10.1016/S1047-2797(00)00144-7
[10]  
GRAFFNERNORDBER.M, 2001, APPROACHES SOFT DRUG